Nature Reviews Immunology 11, 658–671 (2011)
In the original version of this article, in the section under the subheading “CNS-specific NK cells in disease” on page 668, the humanized antibody daclizumab was incorrectly described as being specific for the IL-2 receptor β-chain (CD122). The corrected sentence now reads: “These findings might be relevant to the mode of action of daclizumab, a humanized antibody specific for the IL-2 receptor α-chain (CD25)”. The authors apologize for this error.
About this article
Search for Fu-Dong Shi in:
Search for Hans-Gustaf Ljunggren in:
Search for Antonio La Cava in:
Search for Luc Van Kaer in: